General Biologicals Corporation
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening… Read more
General Biologicals Corporation (4117) - Net Assets
Latest net assets as of June 2025: NT$156.90 Million TWD
Based on the latest financial reports, General Biologicals Corporation (4117) has net assets worth NT$156.90 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.54 Billion) and total liabilities (NT$3.38 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$156.90 Million |
| % of Total Assets | 4.43% |
| Annual Growth Rate | 31.84% |
| 5-Year Change | -58.34% |
| 10-Year Change | N/A |
| Growth Volatility | 350.11 |
General Biologicals Corporation - Net Assets Trend (2019–2024)
This chart illustrates how General Biologicals Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for General Biologicals Corporation (2019–2024)
The table below shows the annual net assets of General Biologicals Corporation from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$286.48 Million | -42.32% |
| 2023-12-31 | NT$496.65 Million | -28.34% |
| 2022-12-31 | NT$693.07 Million | -5.66% |
| 2021-12-31 | NT$734.66 Million | +6.82% |
| 2020-12-31 | NT$687.74 Million | +856.86% |
| 2019-12-31 | NT$71.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to General Biologicals Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5426200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$608.25 Million | 213.73% |
| Other Comprehensive Income | NT$21.47 Million | 7.54% |
| Other Components | NT$87.68 Million | 30.81% |
| Total Equity | NT$284.59 Million | 100.00% |
General Biologicals Corporation Competitors by Market Cap
The table below lists competitors of General Biologicals Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lixiang Education Holding Co Ltd
NASDAQ:LXEH
|
$4.59 Million |
|
FASING SA
WAR:FSG
|
$4.59 Million |
|
Sidomulyo Selaras Tbk
JK:SDMU
|
$4.59 Million |
|
Raubex
JSE:RBX
|
$4.60 Million |
|
Bank Utica Ny Nonvtg
PINK:BKUTK
|
$4.59 Million |
|
Jerusalem
TA:JBNK
|
$4.59 Million |
|
Bodhi Tree Multimedia Limited
NSE:BTML
|
$4.59 Million |
|
GREENROC MINING LS-001
F:3WF
|
$4.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in General Biologicals Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 495,134,000 to 284,587,000, a change of -210,547,000 (-42.5%).
- Net loss of 220,823,000 reduced equity.
- Other comprehensive income increased equity by 5,346,000.
- Other factors increased equity by 4,930,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-220.82 Million | -77.59% |
| Other Comprehensive Income | NT$5.35 Million | +1.88% |
| Other Changes | NT$4.93 Million | +1.73% |
| Total Change | NT$- | -42.52% |
Book Value vs Market Value Analysis
This analysis compares General Biologicals Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.36x to 0.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$1.82 | NT$4.30 | x |
| 2020-12-31 | NT$12.96 | NT$4.30 | x |
| 2021-12-31 | NT$12.21 | NT$4.30 | x |
| 2022-12-31 | NT$11.54 | NT$4.30 | x |
| 2023-12-31 | NT$8.28 | NT$4.30 | x |
| 2024-12-31 | NT$4.76 | NT$4.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently General Biologicals Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -87.65%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 11.97x
- Recent ROE (-77.59%) is below the historical average (-27.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -54.32% | -16.29% | 0.85x | 3.91x | NT$-46.23 Million |
| 2020 | 9.08% | 13.06% | 0.57x | 1.22x | NT$-6.30 Million |
| 2021 | 6.03% | 8.00% | 0.44x | 1.73x | NT$-29.01 Million |
| 2022 | -7.70% | -14.36% | 0.24x | 2.25x | NT$-122.24 Million |
| 2023 | -40.16% | -75.08% | 0.10x | 5.12x | NT$-248.35 Million |
| 2024 | -77.59% | -87.65% | 0.07x | 11.97x | NT$-249.28 Million |
Industry Comparison
This section compares General Biologicals Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| General Biologicals Corporation (4117) | NT$156.90 Million | -54.32% | 21.56x | $4.59 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |